Neuren Pharmaceuticals Limited ( (AU:NEU) ) just unveiled an update.
Neuren Pharmaceuticals Limited has announced an update regarding its ongoing on-market buy-back program. As of the latest announcement, the company has repurchased a total of 1,288,620 securities, with an additional 113,035 securities bought back on the previous day. This buy-back initiative is part of Neuren’s strategy to manage its capital structure and potentially enhance shareholder value.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development and commercialization of therapies for neurodevelopmental disorders. The company is known for its work on treatments targeting conditions such as Rett syndrome and Fragile X syndrome, aiming to address unmet medical needs in these areas.
Average Trading Volume: 590
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $983.7M
Learn more about NEU stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com